Comparison of Conventional Prognostic Indices in Patients Older than 60 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): Consideration of Age Greater than 70 Years in an Elderly Prognostic Index (E-IPI)

Documenti analoghi

• Patterns of Growth Factor Usage and Febrile Neutropenia Among Older Patients with Diffuse Large B-Cell Non-Hodgkin Lymphoma Treated with CHOP or R-CHOP: The Intergroup Experience (CALGB 9793; ECOG-SWOG 4494)
  di: Morrison, Vicki A., et al.
  Pubblicazione: (2016)
• Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Over Age 60 Treated with R-CHOP but not CHOP: A prospective ECOG and SWOG correlative study of E4494
  di: Winter, Jane N., et al.
  Pubblicazione: (2010)
• Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial
  di: Advani, Ranjana H., et al.
  Pubblicazione: (2011)
• Mantle Cell Lymphoma Initial Therapy with Abbreviated R-CHOP Followed by (90)Yibritumomab tiuxetan: Ten year follow-up of the Phase 2 ECOG-ACRIN study E1499
  di: Smith, Mitchell R., et al.
  Pubblicazione: (2016)
• Bevacizumab and CHOP (A-CHOP) in Combination for Patients with Peripheral T-Cell or Natural Killer Cell Neoplasms: An Eastern Cooperative Group Study (E2404)
  di: Ganjoo, Kristen, et al.
  Pubblicazione: (2013)